The U.S. Food and Drug Administration approved WAKIX to treat excessive daytime sleepiness in children aged six and older with narcolepsy, expanding the drug’s potential market.
Despite the regulatory win, Harmony Biosciences shares sold off. The decline was attributed to investors taking profits after a recent run-up ahead of the widely anticipated approval.
The company did not announce any changes to its financial guidance alongside the approval.